A new era in liquid biopsy testing
Introducing Guardant360 Liquid CDx now FDA-Approved
From the #1 liquid biopsy company comes the largest, most comprehensive FDA-approved liquid profiling CDx test with enhanced clinical actionability to help guide more informed treatment decisions1,2*
Home Screening MRD + Monitoring Treatment Selection
MAF, mutant allele fraction.
*Statement applies to Guardant360 Liquid LDT as reported in a professional service report, which is part of Guardant360 Liquid CDx. The professional service report is not reviewed nor approved by the FDA. #1 liquid biopsy statement is based on stated brand utilization from a market research survey.
†Median turnaround time from sample receipt to results.
InfinityAI is not a standalone customer product. “Powered by InfinityAI” refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.
Important note: Guardant360 Liquid was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Guardant360 Liquid is not approved nor marketed in EU.